In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canadian Pharmacare Report Urges Mandatory Substitution

Executive Summary

Recommendations by Canada’s advisory council implementing national pharmacare include mandatory generic substitution and also mechanisms of biosimilar substitution.

You may also be interested in...



Industry Pact Aligns Canadian Prices To International Levels

An agreement between industry and authorities in effect from April last year is already having a major effect in ensuring Canadian generics prices are similar to those in other developed markets, an official report shows.

ASBM Hits Back At British Columbia Switching Scheme

Originator-backed lobbying group the Alliance for Safe Biologic Medicines has raised concerns over a biosimilar switching policy recently unveiled by the Canadian province of British Columbia.

CGPA Points To Lower Prices In Canada

Generics prices in Canada have seen the steepest decline of all OECD countries, the CGPA has highlighted following the release of the latest PMPRB data.

Topics

UsernamePublicRestriction

Register

LL043097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel